Zealand Pharma A/S (CPH:ZEAL)
350.40
+9.30 (2.73%)
Aug 14, 2025, 4:59 PM CET
Zealand Pharma Revenue
Zealand Pharma had revenue of 9.09B DKK in the quarter ending June 30, 2025, with 26,527.65% growth. This brings the company's revenue in the last twelve months to 9.11B, up 2,375.69% year-over-year. In the year 2024, Zealand Pharma had annual revenue of 62.69M, down -81.71%.
Revenue (ttm)
9.11B
Revenue Growth
+2,375.69%
P/S Ratio
2.66
Revenue / Employee
23.66M
Employees
335
Market Cap
24.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
Dec 31, 2020 | 192.00M | 150.67M | 364.52% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Nordisk | 311.94B |
Coloplast | 27.79B |
Genmab | 23.16B |
Demant | 22.42B |
ALK-Abelló | 5.71B |
H. Lundbeck | 22.95B |
Ambu A/S | 5.83B |
Bavarian Nordic | 6.23B |
Zealand Pharma News
- 9 hours ago - Zealand Pharma reports 1H results - Seeking Alpha
- 16 hours ago - Zealand Pharma Announces Financial Results for the First Half of 2025 - GlobeNewsWire
- 7 days ago - Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results - GlobeNewsWire
- 27 days ago - Zealand Pharma major shareholder announcement: Van Herk Investments B.V. - GlobeNewsWire
- 2 months ago - Zealand Pharma Obesity Therapy Shows Positive Trial Results - Market Watch
- 2 months ago - Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide - GlobeNewsWire
- 2 months ago - Zealand Pharma increases its share capital as a result of the exercise of employee warrants - GlobeNewsWire
- 2 months ago - Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome - GlobeNewsWire